Markets.com Logo

GTBP

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    1.132$
  • Previous Close
    1.0687$
  • 52 Week Change
    3.14$
  • Day Range
    0.06$
  • 52 Week High/Low
    0.96$ - 4.1$
  • Dividend Per Share
    --
  • Market cap
    3 535 K$
  • EPS
    -0.55
  • Beta
    1.333
  • Volume
    --

About

GT Biopharma, Inc. (GTBP.US) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapy products based on its TriKE® and TetraKE™ technology platforms. These platforms are designed to harness and enhance the body's natural killer (NK) cell activity to target and eliminate cancer cells. The company's lead TriKE® candidate, GTB-3550, is being evaluated in clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). GT Biopharma is also developing additional TriKE® and TetraKE™ product candidates targeting other hematologic malignancies and solid tumors.

Gold Volatility: Is a Structural Shift Underway? An In-depth Analysis

Noah Lee|--

S&P 500's Record Rally Continues: Nomura Strategist Flags Two Key Exit Signals

Liam James|--

Trump's Papal Challenge: A Clash Over Moral Authority and Political Influence

Noah Lee|--

Global Markets Show Resilience Amidst Iran Conflict, But Underlying Risks Persist

Emma Rose|--

Iran War Threatens US Labor Market's 'Wonderful Balance': A Deep Dive

Emma Rose|--

Iran's Hormuz Toll Strategy: Post-War Economic Leverage and Geopolitical Realignment

Sophia Claire|--

US Labor Market Outlook: Balancing Recovery Against Escalating Geopolitical Risks

Sophia Claire|--

Factors

Clinical Trial Results: Positive or negative outcomes from GT Biopharma's clinical trials significantly impact investor confidence and stock value.

Regulatory Approvals: FDA decisions on GT Biopharma's drug candidates are major catalysts, driving prices up with approvals and down with rejections.

Partnerships and Collaborations: Deals with larger pharmaceutical companies often boost GTBP.US stock by validating their technology and providing funding.

Financial Performance: GT Biopharma's cash position, debt levels, and ability to raise capital influence investor sentiment and stock price.

Market Sentiment: Overall market trends, particularly in the biotechnology sector, can affect GTBP.US regardless of company-specific news.

Competition: Developments from rival companies in the same therapeutic areas can impact GT Biopharma's perceived market share and future prospects.

News and Media Coverage: Positive or negative news articles and media reports can temporarily affect investor behavior and stock volatility.

Analyst Ratings: Recommendations from financial analysts can sway investor decisions, leading to price changes based on their assessments.

Management Changes: Changes in GT Biopharma's leadership can introduce uncertainty, potentially impacting investor confidence and stock valuation.

People Also Watch

Latest news

Japan's Central Bank Poised for Rate Hike Amidst Heightened Middle East Tensions

Ava Grace|--

US Stocks Hit Record Highs as Geopolitical Fears Ease, Tech Bet Surge

Ava Grace|--

Fed Chair Succession Sparks Legal Battle Over Independence

Noah Lee|--

Latest Education Articles

Bonds vs. Stocks in CFD Trading: What Traders Need to Understand

Bonds vs. Stocks in CFD Trading: What Traders Need to Understand

Julian Parker|--
Crypto Trends in 2026: 7 Key Developments Every Investor Should Watch

Crypto Trends in 2026: 7 Key Developments Every Investor Should Watch

Julian Parker|--
Beginners Guide to Fundamental Analysis: What Are the 5 Key Principles of Fundamental Analysis?

Beginners Guide to Fundamental Analysis: What Are the 5 Key Principles of Fundamental Analysis?

Frances Wang|--
Recommended Topics